[ad_1]
The pharmaceutical AstraZeneca decided to discontinue a clinical trial of the Covid-19 vaccine because one of the participants suffered a “potentially unexplained illness”.
The news was confirmed by a spokesman for the pharmaceutical company to the specialized media Statistics, who explained that “this is a routine action that happens whenever there is a potentially unexplained disease in one of the trials while investigating, ensuring that the integrity of the studies is maintained. “
And he added that “work is being done to accelerate the review of this unique incident with the aim of minimize any potential impact on trial plans“.
The volunteer who got sick resides in the UK and the nature of the adverse reaction that he suffered is unknown.
This vaccine is being developed by AstraZeneca together with the University of Oxford and its efficacy it was being tested in the US, Brazil and South Africa after the trial gave positive results in its early stages, when it was tested on a thousand people in the UK.
AstraZeneca had started phase 3 of its trial of the drug known as AZD7442, which is a combination of two monoclonal antibodies (identical antibodies) in the US at the end of Augustaccording to clinicaltrials.gov, a US government registry; while in the UK, Brazil, and South Africa, the vaccine study was between phases 2 and 3.
The vaccine was expected to be available for the first half of 2021 and was considered one of the most advanced in the world by the World Health Organization (WHO).
Along with pharmaceutical companies Pfizer and Moderna, AstraZeneca is one of three companies with phase 3 studies in the US. This is the first time that one of those trials to achieve the Covid-19 vaccine has to be put on hold. for security reasons.
